TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7017492
Drug: Recognised commercial
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recognised commercial preparation (3 tablespoonfuls a day)
Study: 27015720
Drug: Dialectical Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behavior Therapy adapted for adolescents (DBT-A)
Study: 31127612
Drug: DBT-A with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBT-A with more than 3 months follow-up treatment
Study: 19844234
Drug: Lapatinib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib monotherapy (1500 mg once daily)
Study: 17537071
Drug: Conjoint family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjoint family therapy (CFT)
Study: 17537071
Drug: Separated family
Normalized name: serrated swimming crab, cooked preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separated family therapy (SFT)
Study: 17142202
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg + HCTZ 12.5 mg
Study: 17142202
Drug: Olmesartan 20
Normalized name: olmesartan 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 20 mg + HCTZ 12.5 mg
Study: 6594713
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg naloxone
Study: 29777663
Drug: Etonogestrel implant
Normalized name: Etonogestrel Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etonogestrel implant (ENG)
Study: 25722221
Drug: Rosuvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (10 mg/day) plus Metformin (850 mg twice daily after meals)
Study: 25722221
Drug: Rosuvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (10 mg/day) plus Placebo
Study: 19014306
Drug: Outpatient treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient treatments for depression
Study: 11284461
Drug: Divalproex sodium
Normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex sodium (500 mg/day, adjustable after 1-3 days)
Study: 6851655
Drug: Amcinonide ointment
Normalized name: Amcinonide Ointment
DrugBank: Amcinonide (DB00288)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amcinonide ointment 0.1 percent twice a day
Study: 6851655
Drug: Fluocinonide ointment
Normalized name: Fluocinonide Ointment
DrugBank: Fluocinonide (DB01047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinonide ointment 0.05 percent three times a day
Study: 28468770
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (400,000 IU oral vitamin D3, with an additional 200,000 IU if serum 25(OH)D was <100 nmol/L after 4 weeks)
Study: 26042485
Drug: BF Spiromax
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BF Spiromax 160/4.5 μg
Study: 26042485
Drug: BF Turbohaler
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BF Turbohaler 200/6 μg
Study: 26042485
Drug: BF Spiromax
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BF Spiromax 320/9 μg
Study: 26042485
Drug: BF Turbohaler
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BF Turbohaler 400/12 μg
Study: 17407625
Drug: Bisacodyl (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisacodyl (5-10 mg daily)
Study: 17407625
Drug: Sodium picosulphate
Normalized name: Sodium Picosulfate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium picosulphate (5-10 mg daily)
Study: 14627358
Drug: Yogurt supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yogurt supplement (227 grams of commercial yogurt for 8 days)
Study: 14627358
Drug: No yogurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: No yogurt supplement
Study: 1527431
Drug: Cefixime (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime (single oral 400-mg dose)
Study: 1527431
Drug: Ceftriaxone (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (single intramuscular 250-mg dose)
Study: 15763605
Drug: Oxycodone alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone alone
Study: 30734043
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of pioglitazone (titrated to 45 mg daily)
Study: 11437041
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg b.i.d.) with ursodeoxycholic acid (250 mg t.i.d.)
Study: 10489084
Drug: Paradoxical intention
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Paradoxical intention included in treatment program
Study: 10489084
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment program without paradoxical intention
Study: 21716064
Drug: Acamprosate treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate treatment for 12 weeks
Study: 22563952
Drug: Acamprosate treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate treatment
Study: 19734379
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (10 sessions) plus self-care advice
Study: 16409565
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine injection at lunch-time
Study: 16409565
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine injection at dinner-time
Study: 16409565
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine injection at bed-time
Study: 12849652
Drug: Fibrinolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolytic therapy with recurrent MI during index hospitalization
Study: 8730415
Drug: High blood-flow
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High blood-flow (400 ml/min)
Study: 8730415
Drug: Low blood-flow
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low blood-flow (200 ml/min)
Study: 6313024
Drug: Prolonged infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prolonged infusion of suxamethonium during halothane-nitrous oxide anaesthesia
Study: 6313024
Drug: Prolonged infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prolonged infusion of suxamethonium during fentanyl-nitrous oxide anaesthesia
Study: 6313024
Drug: Neostigmine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine administration after stopping suxamethonium infusion
Study: 3914838
Drug: XRT +
Normalized name: Xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: XRT + chemotherapy (concomitant 5-FU during XRT and maintenance 5-FU + MeCCNU)
Study: 3914838
Drug: XRT +
Normalized name: Xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: XRT + chemotherapy
Study: 24787263
Drug: Parent‐Child Interaction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent‐Child Interaction Therapy (PCIT)
Study: 25187584
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (500 mg daily for fifty days)
Study: 22854605
Drug: Immediate-release oral
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release oral diacetylmorphine (DAM)
Study: 16393744
Drug: Slow-release oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release oral morphine
Study: 19717246
Drug: Experimenter-administered cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimenter-administered cocaine (0, 12.5, 25 and 50mg/70 kg, i.v.)
Study: 19717246
Drug: Cocaine self-administration
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine self-administration (0, 12.5 and 25mg/70 kg, i.v.)
Study: 10643347
Drug: Oral high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral high-dose methylprednisolone (500 mg once daily for five days with a 10 days tapering period)
Study: 20597561
Drug: Metoclopramide 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 0.2 mg/kg intravenously
Study: 26997579
Drug: Ondansetron 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.15 mg/kg intravenously
Study: 24835497
Drug: Lidocaine/tetracaine patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine/tetracaine patch
Study: 16022759
Drug: Purified high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified high-dose anthocyanoside oligomer (100 mg tablet comprising 85% anthocyanoside oligomer), administered twice daily for 4 weeks.
Study: 16022759
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered twice daily for 4 weeks.
Study: 2058846
Drug: Naloxone group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone group (group N): 0.4 mg bolus followed by 5 micrograms.kg‐1.h‐1 infusion for 18 hours
Study: 29933343
Drug: Graded Exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded Exercise Therapy (GET) and Resistance Training (RT) program, 12 months duration, exercise sessions at 6 days per week, aerobic exercises with incremental training time, resistance exercises with a durable resistance band.
Study: 27825334
Drug: Danlou tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danlou tablets
Study: 17513394
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g avenanthramide-enriched mixture (AEM)
Study: 17513394
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g avenanthramide-enriched mixture (AEM)
Study: 17513394
Drug: 360 mL
Normalized name: colostomy bags 10" 360 mL MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 mL skim milk (placebo)
Study: 16156111
Drug: IV fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV fentanyl (80 microg/h) administered intermittently over 24 hours
Study: 31472003
Drug: Preventive strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive strategy (oral calcium + vitamin D supplementation)
Study: 31472003
Drug: Reactive strategy
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reactive strategy (therapy in hypocalcemia)
Study: 31472003
Drug: Predictive strategy
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predictive strategy (therapy if iPTH <10 pg/mL)
Study: 28449795
Drug: Bosentan (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan (target dose 125 mg twice daily)
Study: 20933466
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (radiotherapy plus immediate androgen suppression with goserelin acetate)
Study: 17137013
Drug: Gymnastics twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gymnastics twice a week
Study: 12715790
Drug: Edaravone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone (30 mg, twice a day for 14 days)
Study: 9176190
Drug: Progesterone administration
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone administration at 9:30 PM
Study: 3058171
Drug: FUT‐175 (protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: FUT‐175 (protease inhibitor)
Study: 3058171
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose heparinization (LH)
Study: 29316946
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (Control group)
Study: 15519187
Drug: Heparin dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin dosage of 100 iu/kg
Study: 15519187
Drug: Heparin dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin dosage of 200 iu/kg
Study: 15519187
Drug: Heparin dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin dosage of 250 iu/kg
Study: 15519187
Drug: Heparin dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin dosage of 300 iu/kg
Study: 8616834
Drug: GSTM3 AA
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSTM3 AA in combination with skin type 1, GSTM1 null, and CYP1A1 m1m1
Study: 1611985
Drug: 0.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg midazolam, 1.5 mg/kg tramadol, 50 mg alizaprid
Study: 1611985
Drug: 0.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg midazolam, 0.2 mg/kg nalbuphine, 50 mg alizaprid
Study: 4030188
Drug: Testosterone and
Normalized name: testosterone and estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone and anabolic steroids (average 57 +/- 24.9 mg/day for 6 months)
Study: 4030188
Drug: Testosterone and
Normalized name: testosterone and estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone and anabolic steroids
Study: 24337350
Drug: LED therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LED therapy (λ of 640 ± 20 nm and spatial average energy fluency of 1.2 J/cm(2) during hospitalization)
Study: 24337350
Drug: LED therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LED therapy (640 nm)
Study: 11245839
Drug: Attention-based visual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attention-based visual routines involving dynamic patterns (e.g., pairs of points in orbiting motion, 11 points in biological motion)
Study: 9675625
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of morphine
Study: 10381659
Drug: Calcium ointment
Normalized name: calcium undecylenate Topical Ointment
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium ointment (10% w/w calcium carbonate) applied to lower lid skin twice a day
Study: 720774
Drug: Aspirin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (10 gm over four days)
Study: 720774
Drug: Ibuprofen and
Normalized name: Ibuprofen and Famotidine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen and ketoprofen
Study: 10920611
Drug: Prednisolone treatment
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone treatment
Study: 21527597
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) plus 2 months of Tube Feeding (TF)
Study: 15721570
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) alone
Study: 19253241
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia (group T)
Study: 11747472
Drug: Horse-chestnut seeds
Normalized name: horse chestnut seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horse-chestnut seeds extract (HCSE) and compression therapy
Study: 8232429
Drug: CHVP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHVP plus interferon alfa (5 million units three times weekly for 18 months)
Study: 25015215
Drug: Ranibizumab 0.5
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.5 mg monthly
Study: 31718842
Drug: Ranibizumab 0.5
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.5 mg pro re nata (PRN) after 3 loading doses
Study: 25015215
Drug: Ranibizumab 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 2.0 mg monthly
Study: 25015215
Drug: Ranibizumab 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 2.0 mg PRN
Study: 31718842
Drug: All ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All ranibizumab doses
Study: 8694682
Drug: Clomipramine for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine for 9 months combined with 15 weekly sessions of brief dynamic psychotherapy
Study: 1931397
Drug: Adenosine triphosphate
Normalized name: Adenosine triphosphate
DrugBank: ATP (DB00171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine triphosphate (ATP) 0.05 mg kg‐1 or 0.1 mg kg‐1
Study: 6285947
Drug: Large fractions
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large fractions of radiation with high-dose metronidazole
Study: 6285947
Drug: Radiation as
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation as in Group 2 but with equitoxic doses of MISO
Study: 22249844
Drug: PDGF (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDGF (25 ng/ml)
Study: 20218746
Drug: Antiparasitic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiparasitic and anti-infective drugs
Study: 17548704
Drug: Iron intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron intake in women consuming 30+ g of alcohol per day
Study: 17548704
Drug: Iron intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron intake in women who had ever used hormone replacement therapy
Study: 15823510
Drug: Levetiracetam (1000-4000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (1000-4000 mg/day)
Study: 705848
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 200 mg doxycycline
Study: 30643398
Drug: Formoterol fumarate
Normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol fumarate inhalation solution (FFIS; 20 µg, n=541)
Study: 30643398
Drug: Formoterol fumarate
Normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol fumarate inhalation solution (FFIS)
Study: 23442752
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml mepivacaine 1%
Study: 21481449
Drug: Phentermine 7.5
Normalized name: phentermine 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentermine 7.5 mg plus topiramate 46.0 mg
Study: 21481449
Drug: Phentermine 15.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentermine 15.0 mg plus topiramate 92.0 mg
Study: 14652086
Drug: Caffeine+Nap (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine+Nap (200 mg caffeine followed by a 20 min nap)
Study: 11061612
Drug: Gemcitabine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine administered intravenously at 1250 mg/m2 over 30-60 minutes on days 1, 8, and 15 followed by 1 week of rest, maximum of six cycles
Study: 8550052
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa (IFN-alpha) treatment
Study: 29426869
Drug: Open-label placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label placebo (OLP) - 2 placebo pills twice a day for 21 days
Study: 9431710
Drug: Cow udder
Normalized name: Cow milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cow udder ointment
Study: 27668723
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior psychophysiological therapy (CBPT)
Study: 27668723
Drug: Music and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music and relaxation therapy (MRT)
Study: 18940714
Drug: Peppermint and
Normalized name: BODY PRESCRIPTIONS ANTIBACTERIAL HAND SANITIZER 2 Pack PEPPERMINT and WINTER BERRY KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peppermint and neroli hydrolat spray
Study: 18940714
Drug: Plain water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain water spray
Study: 18940714
Drug: Both sprays
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both sprays
Study: 16647152
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with surgery and RT at the time of LRR
Study: 1728203
Drug: Dobutamine (0.38
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine (0.38 mg/kg body weight)
Study: 1728203
Drug: Adenosine (0.84
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (0.84 mg/kg body weight)
Study: 1728203
Drug: Dipyridamole (0.84
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (0.84 mg/kg body weight)
Study: 31499528
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (CEE) (0.625 mg/d)
Study: 27091036
Drug: Helicobacter pylori
Normalized name: HELICOBACTER PYLORI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helicobacter pylori standard treatment for two weeks followed by antacid medication (morning and night) for three months
Study: 27091036
Drug: Antacid medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid medication (morning and night) for four weeks followed by three months of antacid treatment
Study: 25374219
Drug: Hyperglycemia group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycemia group (fasting glucose≥126 mg/dl and/or random blood glucose≥200 mg/dl)
Study: 17653959
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HRT) with 2 mg 17beta-estradiol/10 mg dydrogesterone (Femoston) for seven 28-day cycles
Study: 16563251
Drug: Celecoxib (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (10 micromol/L)
Study: 10087460
Drug: Theophylline (Respicur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (Respicur retard(R) 400 mg) therapy
Study: 7754404
Drug: Intermittent cryotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent cryotherapy (standard therapy with cool packs)
Study: 2181915
Drug: Amoxicillin +
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin + clavulanic acid (40 mg/kg/day in 3 or 4 divided doses)